GRIK3 and cancer: Glutamate receptor kainate 3 (GRIK3) promotes epithelial-mesenchymal transition (EMT) in cancers, correlating with poor prognosis, and is overexpressed in GH-secreting pituitary tumors, indicating potential aggressiveness (49, 50).